Upexi UPXI Gain Loss From The Sale Of Vita Medica
Gain Loss From The Sale Of Vita Medica at other companies
Other financials
Where this comes from
Reported directly by Upexi in its filing.
Tagged under the XBRL concept upxi:GainLossFromTheSaleOfVitaMedica.
The official record: Upexi’s 10-K, filed September 24, 2025, on SEC EDGAR. View the filing →
Ask your AI about Upexi's gain loss from the sale of vita medica.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Upexi's gain loss from the sale of vita medica?
- Upexi (UPXI) reported gain loss from the sale of vita medica of $0 in Q2 2025.
- How has Upexi's gain loss from the sale of vita medica changed year-over-year?
- Upexi's gain loss from the sale of vita medica decreased by 100.0% year-over-year, from $487.13K to $0.
- What does gain loss from the sale of vita medica mean?
- Reflects the net financial gain or loss resulting from the disposal of the Vita Medica business line. This figure highlights the effectiveness of the company's strategic divestment strategy and its ability to realize value from non-core or underperforming assets. Monitoring this metric helps stakeholders understand the impact of specific business unit exits on the company's bottom line.